Navigation Links
Study Links Cancerous Tumors With Depression
Date:5/20/2009

Research with rats finds biological tie between growths and mood changes

WEDNESDAY, May 20 (HealthDay News) -- Doctors have long known that people with cancer often suffer from depression.

A new study in rats has found that the cause of the depression may be the properties of the tumor itself, rather than emotional distress over the diagnosis or side effects from chemotherapy.

The study is the first to identify a biological link between tumors and negative mood changes, according to the researchers, who published their study in the May 18 issue of the Proceedings of the National Academy of Sciences.

About 15 percent to 20 percent of patients diagnosed with cancer experience depression, according to the U.S. National Cancer Institute.

Researchers put about 100 rats through a series of exercises commonly used by researchers testing antidepressants in animal models. Some of the rats had cancerous tumors.

The investigators found that the rats with tumors were less motivated to escape when submitted to a swimming test, a condition that is similar to depression in humans. The rats with tumors also were less eager to drink sugar water, a substance that healthy rats usually find irresistible.

"In this case, examining behavioral responses to tumors in non-human animals is particularly useful, because the rats have no awareness of the disease, and thus their behavioral changes were likely the result of purely biological factors," said senior study author Brian Prendergast, associate professor of psychology at the University of Chicago.

The team determined that substances associated with depression are produced in increased quantities by tumors and are transmitted to the brain.

Additionally, pathways that normally moderate the impact of depression-causing substances are disrupted when a tumor develops.

Tumors induce changes in gene expression in the hippocampus, the portion of the brain that regulates emotion.

Rats with tumors had increased levels of cytokines in their blood and in the hippocampus when compared with healthy rats. Previous research has linked high levels of cytokines, which are produced by the immune system, to depression.

The research team also found that stress hormone production was altered in rats with tumors.

The rats with tumors had dampened production of the stress hormone corticosterone, which helps regulate the impact of cytokines. Reducing the production of corticosterone may increase the impact of cytokines.

"Our research shows that two types of tumor-induced molecules, one secreted by the immune system and another by the stress axis, may be responsible," said Leah Pyter, a postdoctoral fellow at the University of Chicago and lead study author. "Both of these substances have been implicated in depression, but neither has been examined over time frames and magnitudes that are characteristic of chronic diseases such as cancer."

More information

The U.S. National Cancer Institute has more on cancer and depression.



-- Jennifer Thomas



SOURCE: University of Chicago, news release, May 18, 2009


'/>"/>
Copyright©2009 ScoutNews,LLC.
All rights reserved  

Related medicine news :

1. New Study Reveals Wide Variations in Depression Diagnoses among Ethnic Groups
2. HIMSS Analytics and NetMotion Wireless Release Study Findings on Key Challenges for Wireless Healthcare Deployments
3. Stem Cell Study Offers Hope for Targeting Tumors
4. Study Reiterates Eye Risks Linked to Flomax
5. Study Shows NeuroStar TMS Therapy(R) Improved Key Elements of Cognition in Patients with Major Depressive Disorder
6. BioHorizons Reports on Comparative 3-Year Dental Implant Study Showing Significant Crestal Bone and Soft Tissue Retention Using Laser-Lok(R) Microchannels
7. Results of phase III study on Labopharms novel antidepressant published in Psychiatry (Edgemont) Journal
8. SYNTAX Substudy Shows Positive Outcomes for Left Main Patients Treated With TAXUS(R) Express2(R) Stent System
9. MS Patients More Compliant with Medications When Managed by Specialty Pharmacy, According to HealthCore Study Presented at ISPOR
10. Deloitte Comparative Effectiveness Study Evaluates Potential Savings Opportunities for U.S. Health Care System
11. Workplace E-Mail Intervention Program Helps People Sit Less and Eat Better, Kaiser Permanente Study Finds
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Study Links Cancerous Tumors With Depression
(Date:6/26/2016)... ... 26, 2016 , ... Pixel Film Studios Released ProSlice Levels, a Media Slicing ... their videos a whole new perspective by using the title layers in ProSlice ... , ProSlice Levels contains over 30 Different presets to choose from. FCPX ...
(Date:6/26/2016)... ... June 26, 2016 , ... ... they have been diagnosed with endometriosis. These women need a treatment plan to ... a comprehensive approach that can help for preservation of fertility and ultimately achieving ...
(Date:6/25/2016)... Miami, FL (PRWEB) , ... June 25, 2016 , ... The temporary closing of Bruton ... Plant City Observer , brings up a new, often overlooked aspect of head lice: ... The closing for fumigation is not a common occurrence, but a necessary one in the ...
(Date:6/25/2016)... ... , ... As a lifelong Southern Californian, Dr. Omkar Marathe earned his Bachelors ... Geffen School of Medicine at UCLA. He trained in Internal Medicine at Scripps Green ... hematology/oncology at the UCLA-Olive View-Cedars Sinai program where he had the opportunity to train ...
(Date:6/25/2016)... Montreal, Canada (PRWEB) , ... June 25, 2016 , ... ... the pursuit of success. In terms of the latter, setting the bar too high ... low, risk more than just slow progress toward their goal. , Research from ...
Breaking Medicine News(10 mins):
(Date:6/26/2016)... June 27, 2016 Jazz Pharmaceuticals plc (Nasdaq: ... under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as ... Celator Pharmaceuticals, Inc. ("Celator"; Nasdaq: CPXX ) ... Daylight Time). As previously announced on May ... definitive merger agreement under which Jazz Pharmaceuticals has commenced ...
(Date:6/24/2016)... 24, 2016  Global Blood Therapeutics, Inc. (GBT) (NASDAQ: ... novel therapeutics for the treatment of grievous blood-based ... closing of its previously announced underwritten public offering ... public offering price of $18.75 per share. All ... by GBT. GBT estimates net proceeds from the ...
(Date:6/24/2016)... -- Dehaier Medical Systems Ltd. (NASDAQ: DHRM ... sells medical devices and wearable sleep respiratory products in ... agreement with Hongyuan Supply Chain Management Co., Ltd. (hereinafter ... 2016, to develop Dehaier,s new Internet medical technology business. ... leverage Hongyuan Supply Chain,s sales platform to reach Dehaier,s ...
Breaking Medicine Technology: